RxDoctor Payments Data

Eric Brahin, MD

Neurology · San Antonio, TXNPI 1710201264

Payments from drug & device makers

$27,543in general payments, 2019–2025

Across 1,430 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$2K
  • Novartis$2K
  • EMD Serono, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Acadia Pharmaceuticals Inc$1K
  • plus $18K from 54 others

What the payments were for

  • Speaking & faculty fees$1200%
  • Food & beverage$27,40199%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)118$1,822
UCB, Inc.72$1,662
Novartis86$1,592
EMD Serono, Inc.95$1,583
Teva Pharmaceuticals USA, Inc.124$1,566
Acadia Pharmaceuticals Inc65$1,390
Bristol Myers Squibb58$1,353
Biogen59$1,315
Livanova USA, Inc.59$1,228
Amneal Pharmaceuticals LLC59$1,056
Pfizer50$1,030
Genentech USA, Inc.47$1,010
Amgen49$937
SK Life Science, Inc.29$689
Eisai Inc.30$632
Jazz Pharmaceuticals Inc.23$623
TG Therapeutics, Inc.30$621
Neurocrine Biosciences, Inc.32$574
Sunovion Pharmaceuticals Inc.35$547
Lundbeck LLC24$544
Akcea Therapeutics, Inc.16$539
AstraZeneca(2 entities)23$517
Supernus Pharmaceuticals, Inc.40$463
Lilly USA, LLC20$372
MDD US Operations, LLC15$347
Argenx US, Inc.12$299
Sanofi11$237
Adamas Pharmaceuticals, Inc.15$235
Abbott9$222
Sumitomo Pharma America, Inc.12$208
Tanabe Pharma America, Inc.10$206
Otsuka America Pharmaceutical, Inc.7$159
Biohaven Pharmaceutical Holding Company Ltd.8$142
CSL Behring7$137
Catalyst Pharmaceuticals, Inc.6$128
Biohaven Pharmaceuticals, Inc.5$120
Acorda Therapeutics, Inc6$120
E.r. Squibb & Sons, L.L.C.5$104
Upsher-smith Laboratories LLC5$103
Avanir Pharmaceuticals, Inc.5$101
Impel Pharmaceuticals Inc.5$96
Aquestive Therapeutics, Inc.4$84
Kyowa Kirin, Inc.4$79
Boston Scientific2$67
Xeris Pharmaceuticals, Inc.3$66
Immedica Pharma US, Inc.2$59
Insightec,inc2$54
Aprecia Pharmaceuticals, LLC3$52
Averitas Pharma Inc.2$51
Avion Pharmaceuticals2$47
Vanda Pharmaceuticals Inc.2$47
Amylyx Pharmaceuticals, Inc.2$40
Johnson & Johnson2$33
Vertical Pharmaceuticals, LLC2$29
Takeda Pharmaceuticals U.S.A., Inc.1$26
Neurelis, Inc.1$25
Impel Pharmaceuticals LLC1$23
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$22
Springworks Therapeutics, Inc.1$18
GRT US Holding, Inc.2$18

How this compares

$27,543 in reported general payments places this provider in the 75th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$148,104
Medicare patients
293
Services billed
730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate22$189,404
UbrelvyUbrogepant129$147,187
NuplazidPimavanserin Tartrate27$123,525
Kesimpta PenOfatumumab14$118,698
IngrezzaValbenazine Tosylate13$99,807
AptiomEslicarbazepine Acetate60$78,112
Nurtec OdtRimegepant Sulfate66$77,583
Aimovig AutoinjectorErenumab-Aooe80$70,398
GlatopaGlatiramer Acetate13$59,707
BriviactBrivaracetam33$58,496
OnfiClobazam19$57,847
FycompaPerampanel40$45,484
Emgality PenGalcanezumab-Gnlm65$42,801
BotoxOnabotulinumtoxina27$42,694
VimpatLacosamide29$39,433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Botox, Qulipta, Namzaric$1,822$226,922192 claims
BiogenVumerity$1,315$189,40422 claims
Acadia Pharmaceuticals IncNuplazid$1,390$123,52527 claims
Neurocrine Biosciences, Inc.Ingrezza$574$99,80713 claims
UCB, Inc.Briviact, Vimpat$1,662$97,93062 claims
Sunovion Pharmaceuticals Inc.Aptiom$547$78,11260 claims
PfizerNurtec Odt$1,030$77,58366 claims
Lundbeck LLCOnfi$544$57,84719 claims
Eisai Inc.Fycompa$632$45,48440 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$1,056$19,68653 claims
Upsher-smith Laboratories LLCTopiramate$103$3,418468 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,246 neurology providers in Texas.

Other neurology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →